Heterocyclic Naphthoquinones Derivatives for Use in the Treatment of Cancers Including Cushing Disease
AssigneesCommissariat A L'energie Atomique Et Aux Energies Alternatives, Universite Grenoble Alpes, Universite D'Aix-Marseille
InventorsMarie-Odile Fauvarque, Magda Mortier, Catherine Pillet, Carmen Aguilar, Emmanuelle Soleilhac, Caroline Barette, Vincent Remusat, Thierry Terme, Patrice Vanelle
Life of this patent
Estimating the term…
Abstract
The present invention concerns heterocyclic naphthoquinones derivatives for use in the treatment of Cushing disease and other cancers, in particular via the inhibition of Ubiquitin Specific Proteases (USP) 8 and/or 2.
Claims16
A method for the treatment of cancer comprising administration to a subject in need thereof a compound of formula (I):
- wherein:
- A is selected from the group comprising:
- Ra and Rb each independently represent:
- when A is A1 or A3, a group of one of the following formulae:
- when A is A2, H or a group of one of the following formulae:
- provided that at least one of Ra and Rb is not H;
- RY and RZ each independently represent H, a C1-C10 linear or branched alkyl group, a C3-C10 cycloalkyl group, or together form with the carbon atom to which they are attached a C3-C10 cycloalkyl group;
- X represents Cl or a group the following formula:
- RX represents a C1-C10 linear or branched alkyl group, a C3-C10 cycloalkyl group, an aryl group, in particular a phenyl or naphtyl group, a C5-C10-membered heteroaryl;
- said C1-C10 linear or branched alkyl group, and C3-C10 cycloalkyl group being optionally substituted by at least one group selected from:
- a C3-C10 cycloalkyl group;
- a phenyl optionally substituted by at least one group selected from a C1-C10 linear or branched alkyl group, a C3-C10 cycloalkyl group, an halogen, a —ORii group, an amine of formula —NRii′Rii″, a nitrile or a nitro group;
- a —ORi group;
- an amine of formula —NRi′Ri″;
- said aryl and C5-C10-membered heteroaryl being optionally substituted by at least one group selected from:
- a C1-C10 linear or branched alkyl group;
- a C3-C10 cycloalkyl group;
- a phenyl optionally substituted by at least one group selected from a C1-C10 linear or branched alkyl group, a C3-C10 cycloalkyl group, an halogen, a —ORii group, an amine of formula —NRii′Rii″, a nitrile or a nitro group;
- an halogen;
- a —ORi group;
- two adjacent —ORi groups forming possibly with the two C atoms bearing said —ORi groups a 1,4-dioxane ring;
- an amine of formula —NRi′Ri″;
- a nitrile;
- a nitro group;
- a CF3 group;
- Ri and Rii each independently represent H, a C1-C10 linear or branched alkyl group, a C3-C10 cycloalkyl group;
- Ri′ and Ri″ each independently represent H, a C1-C10 linear or branched alkyl group, a C3-C10 cycloalkyl group, or together form with the nitrogen atom to which they are attached a C4-C7 heterocycloalkyl group;
- Rii′ and Rii″ each independently represent H, a C1-C10 linear or branched alkyl group, a C3-C10 cycloalkyl group, or together form with the nitrogen atom to which they are attached a C4-C7 heterocycloalkyl group.
A pharmaceutical composition comprising
- a compound of following formula (I), or
- a stereoisomeric form, a mixture of stereoisomeric forms or a pharmaceutically acceptable salt form thereof,
- in admixture with at least one pharmaceutically acceptable excipient.
- wherein:
- A is selected from the group comprising:
- Ra and Rb each independently represent:
- when A is A1 or A3, a group of one of the following formulae:
- when A is A2, H or a group of one of the following formulae:
- provided that at least one of Ra and Rb is not H;
- RY and RZ each independently represent H, a C1-C10 linear or branched alkyl group, a C3-C10 cycloalkyl group, or together form with the carbon atom to which they are attached a C3-C10 cycloalkyl group;
- X represents Cl or a group of the following formula:
- RX represents a C1-C10 linear or branched alkyl group, a C3-C10 cycloalkyl group, a aryl, a C5-C10-membered heteroaryl;
- said C1-C10 linear or branched alkyl group, and C3-C10 cycloalkyl group being optionally substituted by at least one group selected from:
- a C3-C10 cycloalkyl group;
- a phenyl optionally substituted by at least one group selected from a C1-C10 linear or branched alkyl group, a C3-C10 cycloalkyl group, an halogen, a —ORii group, an amine of formula —NRii′Rii″, a nitrile or a nitro group;
- a —ORi group;
- an amine of formula —NRi′Ri″;
- said aryl and C5-C10-membered heteroaryl being optionally substituted by at least one group selected from:
- a C1-C10 linear or branched alkyl group;
- a C3-C10 cycloalkyl group;
- a phenyl optionally substituted by at least one group selected from a C1-C10 linear or branched alkyl group, a C3-C10 cycloalkyl group, an halogen, a —ORii group, an amine of formula —NRii′Rii″, a nitrile or a nitro group;
- an halogen;
- a —ORi group;
- two adjacent —ORi groups forming possibly with the two C atoms bearing said —ORi groups a 1,4-dioxane ring;
- an amine of formula —NRi′Ri″;
- a nitrile;
- a nitro group;
- a CF3 group;
- Ri and Rii each independently represent H, a C1-C10 linear or branched alkyl group, a C3-C10 cycloalkyl group;
- Ri′ and Ri″ each independently represent H, a C1-C10 linear or branched alkyl group, a C3-C10 cycloalkyl group, or together form with the nitrogen atom to which they are attached a C4-C7 heterocycloalkyl group;
- Rii′ and Rii″ each independently represent H, a C1-C10 linear or branched alkyl group, a C3-C10 cycloalkyl group, or together form with the nitrogen atom to which they are attached a C4-C7 heterocycloalkyl group.
A compound of following formula (II):
- wherein:
- A is selected from the group comprising:
- Ra and Rb each independently represent:
- when A is A1 or A3, a group of one of the following formulae:
- when A is A2, H or a group of one of the following formulae:
- provided that at least one of Ra and Rb is not H;
- RY and RZ each independently represent H, a C1-C10 linear or branched alkyl group, a C3-C10 cycloalkyl group, or together form with the carbon atom to which they are attached a C3-C10 cycloalkyl group;
- X represents Cl or a group of the following formula:
- RX represents a C1-C10 linear or branched alkyl group, a C3-C10 cycloalkyl group, a aryl, a C5-C10-membered heteroaryl;
- said C1-C10 linear or branched alkyl group, and C3-C10 cycloalkyl group being optionally substituted by at least one group selected from:
- a C3-C10 cycloalkyl group;
- a phenyl optionally substituted by at least one group selected from a C1-C10 linear or branched alkyl group, a C3-C10 cycloalkyl group, an halogen, a —ORii group, an amine of formula —NRii′Rii″, a nitrile or a nitro group;
- a —ORi group;
- an amine of formula —NRi′Ri″;
- said aryl and C5-C10-membered heteroaryl being optionally substituted by at least one group selected from:
- a C1-C10 linear or branched alkyl group;
- a C3-C10 cycloalkyl group;
- a phenyl optionally substituted by at least one group selected from a C1-C10 linear or branched alkyl group, a C3-C10 cycloalkyl group, an halogen, a —ORii group, an amine of formula —NRii′Rii″, a nitrile or a nitro group;
- an halogen;
- a —ORi group;
- two adjacent —ORi groups forming possibly with the two C atoms bearing said —ORi groups a 1,4-dioxane ring;
- an amine of formula —NRi′Ri″;
- a nitrile;
- a nitro group;
- a CF3 group;
- Ri and Rii each independently represent H, a C1-C10 linear or branched alkyl group, a C3-C10 cycloalkyl group;
- Ri′ and Ri″ each independently represent H, a C1-C10 linear or branched alkyl group, a C3-C10 cycloalkyl group, or together form with the nitrogen atom to which they are attached a C4-C7 heterocycloalkyl group;
- Rii′ and Rii″ each independently represent H, a C1-C10 linear or branched alkyl group, a C3-C10 cycloalkyl group, or together form with the nitrogen atom to which they are attached a C4-C7 heterocycloalkyl group;
- and the stereoisomeric forms, mixtures of stereoisomeric forms or pharmaceutically acceptable salts forms thereof;
- provided that said compound is not of one of the following formulae:
Dependencies are inferred from the claim text.